Condition
Peripheral T-cell Lymphomas (PTCL)
Total Trials
4
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
4Total
Early P 1 (1)
P 1 (2)
P 2 (1)
Trial Status
Active Not Recruiting1
Not Yet Recruiting1
Terminated1
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07279584Phase 2Not Yet RecruitingPrimary
Golidocitinib Combined With GemOx in RR PTCL
NCT02223208Phase 1Active Not RecruitingPrimary
Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas
NCT05105412Phase 1TerminatedPrimary
Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas
NCT04767308Early Phase 1Unknown
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
Showing all 4 trials